Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 71

1.

Endogenous and exogenous galectin-3 promote the adhesion of tumor cells with low expression of MUC1 to HUVECs through upregulation of N-cadherin and CD44.

Cao Z, Hao Z, Xin M, Yu L, Wang L, Zhang Y, Zhang X, Guo X.

Lab Invest. 2018 Aug 31. doi: 10.1038/s41374-018-0119-3. [Epub ahead of print]

PMID:
30171204
2.

Modified Citrus Pectin as a Potential Sensitizer for Radiotherapy in Prostate Cancer.

Conti S, Vexler A, Hagoel L, Kalich-Philosoph L, Corn BW, Honig N, Shtraus N, Meir Y, Ron I, Eliaz I, Lev-Ari S.

Integr Cancer Ther. 2018 Jul 25:1534735418790382. doi: 10.1177/1534735418790382. [Epub ahead of print]

PMID:
30043669
3.

The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment.

Farhad M, Rolig AS, Redmond WL.

Oncoimmunology. 2018 Feb 20;7(6):e1434467. doi: 10.1080/2162402X.2018.1434467. eCollection 2018. Review.

4.

Clean Colorectum at Diagnostic Colonoscopy: Subsequent Detection of Extracolonic Malignancies by Plasma Protein Biomarkers?

Wilhelmsen M, Christensen IJ, Jørgensen LN, Madsen MR, Vilandt J, Hillig T, Klærke M, Nielsen KT, Laurberg S, Gawel S, Yang X, Davis G, Heijboer AM, Martens F, Nielsen HJ.

Biomark Cancer. 2018 May 30;10:1179299X18776974. doi: 10.1177/1179299X18776974. eCollection 2018.

5.

Differential expression of PIWIL2 in papillary thyroid cancers.

Erdogdu IH, Yumrutas O, Ozgur Cevik M, Bozgeyik I, Erdogdu M, Inan HM, Bagis H.

Gene. 2018 Apr 5;649:8-13. doi: 10.1016/j.gene.2018.01.066. Epub 2018 Jan 31.

PMID:
29369786
6.

Galectin-3 and cancer stemness.

Nangia-Makker P, Hogan V, Raz A.

Glycobiology. 2018 Apr 1;28(4):172-181. doi: 10.1093/glycob/cwy001.

PMID:
29315388
7.

Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.

Dondoo TO, Fukumori T, Daizumoto K, Fukawa T, Kohzuki M, Kowada M, Kusuhara Y, Mori H, Nakatsuji H, Takahashi M, Kanayama HO.

Anticancer Res. 2017 Jan;37(1):125-134.

PMID:
28011482
8.

The influence of PSA autoantibodies in prostate cancer patients: a prospective clinical study-II.

Nakajima K, Heilbrun LK, Smith D, Hogan V, Raz A, Heath E.

Oncotarget. 2017 Mar 14;8(11):17643-17650. doi: 10.18632/oncotarget.12620.

9.

Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I.

Nakajima K, Heilbrun LK, Hogan V, Smith D, Heath E, Raz A.

Oncotarget. 2016 Dec 13;7(50):82266-82272. doi: 10.18632/oncotarget.12619.

10.

Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis.

Nakajima K, Kho DH, Yanagawa T, Harazono Y, Hogan V, Chen W, Ali-Fehmi R, Mehra R, Raz A.

Cancer Res. 2016 Mar 15;76(6):1391-402. doi: 10.1158/0008-5472.CAN-15-1793. Epub 2016 Feb 2.

11.

Differences in urinary proteins related to surgical margin status after radical prostatectomy.

Heger Z, Michalek P, Guran R, Cernei N, Duskova K, Vesely S, Anyz J, Stepankova O, Zitka O, Adam V, Kizek R.

Oncol Rep. 2015 Dec;34(6):3247-55.

PMID:
26503549
12.

G3-C12 Peptide Reverses Galectin-3 from Foe to Friend for Active Targeting Cancer Treatment.

Sun W, Li L, Yang Q, Shan W, Zhang Z, Huang Y.

Mol Pharm. 2015 Nov 2;12(11):4124-36. doi: 10.1021/acs.molpharmaceut.5b00568. Epub 2015 Sep 29.

PMID:
26393405
13.

Galectin-3 Overrides PTRF/Cavin-1 Reduction of PC3 Prostate Cancer Cell Migration.

Meng F, Joshi B, Nabi IR.

PLoS One. 2015 May 5;10(5):e0126056. doi: 10.1371/journal.pone.0126056. eCollection 2015.

14.

Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer.

Yang Q, Yang Y, Li L, Sun W, Zhu X, Huang Y.

ACS Appl Mater Interfaces. 2015 Apr 1;7(12):6661-73. doi: 10.1021/am509204u. Epub 2015 Mar 23.

PMID:
25775367
15.

Identification and validation of potential new biomarkers for prostate cancer diagnosis and prognosis using 2D-DIGE and MS.

Geisler C, Gaisa NT, Pfister D, Fuessel S, Kristiansen G, Braunschweig T, Gostek S, Beine B, Diehl HC, Jackson AM, Borchers CH, Heidenreich A, Meyer HE, Knüchel R, Henkel C.

Biomed Res Int. 2015;2015:454256. doi: 10.1155/2015/454256. Epub 2015 Jan 15.

16.

Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.

GuhaThakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher TC, Hall SJ, Kantoff PW, Higano CS, Small EJ, Gardner TA, Bailey K, Vu T, DeVries T, Whitmore JB, Frohlich MW, Trager JB, Drake CG.

Clin Cancer Res. 2015 Aug 15;21(16):3619-30. doi: 10.1158/1078-0432.CCR-14-2334. Epub 2015 Feb 3.

17.

Galectin-3 inhibits osteoblast differentiation through notch signaling.

Nakajima K, Kho DH, Yanagawa T, Harazono Y, Gao X, Hogan V, Raz A.

Neoplasia. 2014 Nov 20;16(11):939-49. doi: 10.1016/j.neo.2014.09.005. eCollection 2014 Nov.

18.

Examination of the regulation of galectin-3 expression in cancer.

Ahmed H, Bandyopadhyaya G.

Methods Mol Biol. 2015;1207:355-69. doi: 10.1007/978-1-4939-1396-1_24.

PMID:
25253153
19.

Proteolytic activity of prostate-specific antigen (PSA) towards protein substrates and effect of peptides stimulating PSA activity.

Mattsson JM, Ravela S, Hekim C, Jonsson M, Malm J, Närvänen A, Stenman UH, Koistinen H.

PLoS One. 2014 Sep 19;9(9):e107819. doi: 10.1371/journal.pone.0107819. eCollection 2014.

20.

Targeting prostate carcinoma by G3-C12 peptide conjugated N-(2-hydroxypropyl)methacrylamide copolymers.

Yang Y, Li L, Zhou Z, Yang Q, Liu C, Huang Y.

Mol Pharm. 2014 Oct 6;11(10):3251-60. doi: 10.1021/mp500083u. Epub 2014 Jun 30.

PMID:
24955652

Supplemental Content

Loading ...
Support Center